Contact Us Today!

617-523-7900

or Use Our Simple Online Form to Give Us Feedback

We welcome your comments and feedback. Please include contact information if you'd like a response.

Did you find this page helpful?





If you would like a response, please include your contact information.

<< Return to Search Results

Ivana K. Kim, M.D.

Photo of Ivana K. Kim, M.D.
Co-Director, Macular Degeneration Unit
Specialties: Retina
Macular Degeneration Unit
Diabetic Retinopathy
Ophthalmic Oncology
Phone Number: 617-573-3367
Fax: 617-573-3678
Location: Massachusetts Eye and Ear
243 Charles Street
Boston, MA 02114
Office Hours: Monday afternoons, Wednesday mornings, Thursday afternoons
Board Certification: Ophthalmology
Medical School Harvard Medical School
Residency Ophthalmology, Harvard Medical School
Fellowship Vitreoretinal Surgery, Mass. Eye and Ear
Teaching Affiliation Associate Professor in Ophthalmology, Harvard Medical School
Biographical Profile:


Ivana K. Kim, M.D., is a full-time clinician scientist in the Retina Service at Mass. Eye and Ear, an Associate Professor of Ophthalmology with Harvard Medical School, and the Evangelos S. Gragoudas Distinguished Scholar in Retina.

Clinical Interests

Diseases and surgery of the retina and vitreous, diabetic retinopathy, macular degeneration, retinal detachment

Research Interests

Macular degeneration, ocular angiogenesis, molecular genetics of uveal melanoma

Publications

For a full publication list, please see her CV. A representative list (2006 - 2012) is available through www.pubmed.gov.

Heier JS, Brown D, Ciulla T, Abraham P, Bankert JM, Chong S, Daniel PE Jr, Kim IK. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology. 2011 Jan; 118(1): 111-8.

Lukason M, DuFresne E, Rubin H, Pechan P, Li Q, Kim I, Kiss S, Flaxel C, Collins M, Miller J, Hauswirth W, Maclachlan T, Wadsworth S, Scaria A. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther. 2011 Feb; 19(2): 260-5.

CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19; 364 (20): 1897-908.

Feehan M, Hartman J, Durante R, Morrison MA, Miller JW, Kim IK, DeAngelis MM. Identifying subtypes of patients with neovascular age-related macular degeneration by genotypic and cardiovascular risk characteristics. BMC Med Genet. 2011 Jun 17; 12: 83.

Chen L, Miller JW, Vavvas D, Kim IK. Anti-vascular endothelial growth factor monotherapy versus combination treatment with photodynamic therapy for subfoveal choroidal neovascularization secondary to causes other than age-related macular degeneration. Retina. 2011 Nov; 31(10): 2078-83.

To learn more about Dr. Kim, click here to read her “Meet a Specialist” profile.